Despite the evidence on safety and efficacy, getting some local medicines management and prescribers to accept varenicline as an equal first-line treatment option was in some cases difficult.
This briefing published in 2013 was intended as a resource for commissioners, managers and staff of stop smoking services and is set out as answers to a series of questions.
This document was written about, and based upon evidence from research investigating, Champix. Generic versions of varenicline are now available and the evidence in this briefing, and the conclusions drawn, are equally applicable to generic varenicline.